CytoMed Therapeutics GDTC
NASDAQ GDTC
$0.92 +0.02 (+2.23%)
At close: Oct 2, 2026 · 4:00 PM EDT

CytoMed Therapeutics (GDTC) Non-Current Deffered Revenue (2026)

Updated

Analysis

CytoMed Therapeutics (GDTC) Non-Current Deffered Revenue (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 CytoMed Therapeutics 9.94 Mn -1.15 Mn - 2,099.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2,099.00
API Access

CytoMed Therapeutics Non-Current Deffered Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=GDTC&period=max&api_key=YOUR_API_KEY